News25/Ratings0
News · 26 weeks40-29%
2025-12-282026-06-21
Mix2190d
- SEC Filings10(48%)
- Other8(38%)
- Insider2(10%)
- Earnings1(5%)
Latest news
25 items- SECSEC Form EFFECT filed by NewcelX Ltd.EFFECT - NewcelX Ltd. (0001783036) (Filer)
- SECSEC Form 6-K filed by NewcelX Ltd.6-K - NewcelX Ltd. (0001783036) (Filer)
- PRNewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology PlatformStudy published in Stem Cell Reports demonstrates that AstroRx® - a therapy derived from NewcelX's platform - addresses key barriers to remyelination with potential to treat chronic demyelinating diseases including MS Showcases scalability and broad therapeutic potential of the Company's stem cell therapy platform as it advances a potential cure for type 1 diabetes ZURICH, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the publication of a peer-reviewed study in Stem Cell Reports, investigating the potential of AstroRx®, a clinical-grade human embryonic stem
- SECAmendment: SEC Form F-3/A filed by NewcelX Ltd.F-3/A - NewcelX Ltd. (0001783036) (Filer)
- SECSEC Form 6-K filed by NewcelX Ltd.6-K - NewcelX Ltd. (0001783036) (Filer)
- SECSEC Form 6-K filed by NewcelX Ltd.6-K - NewcelX Ltd. (0001783036) (Filer)
- PRNewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 DiabetesPre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the submission of a Pre-Investigational New Drug ("Pre-IND") briefing package to the U.S. Food and Drug Administration ("FDA") to support the proposed First-In-Human ("FIH") clinical trial of NCEL-101 in combination with tegoprubart, an investigational immunomodulatory agent being developed by Eledon Pharmaceuticals (("Eledon", NASDAQ:ELDN). The submission represents a significant mi
- SECSEC Form EFFECT filed by NewcelX Ltd.EFFECT - NewcelX Ltd. (0001783036) (Filer)
- SECSEC Form D filed by NewcelX Ltd.D - NewcelX Ltd. (0001783036) (Filer)
- SECSEC Form F-3 filed by NewcelX Ltd.F-3 - NewcelX Ltd. (0001783036) (Filer)
- SECSEC Form EFFECT filed by NewcelX Ltd.EFFECT - NewcelX Ltd. (0001783036) (Filer)
- SECSEC Form POS AM filed by NewcelX Ltd.POS AM - NewcelX Ltd. (0001783036) (Filer)
- SECSEC Form 6-K filed by NewcelX Ltd.6-K - NewcelX Ltd. (0001783036) (Filer)
- PRNewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026NewcelX and Eledon Pharmaceuticals are collaborating to advance one of the few scalable approaches to a potential functional cure in Type 1 Diabetes, NCEL-101, as the flagship program and key long-term value driver toward IND-enabling milestones Substantially debt free, NewcelX recently closed a financing of up to approximately $3.4 million, including $1.35 million in cash and approximately $2 million of potential additional proceeds from the exercise of warrants, and has access to up to a $25 million Equity Line of Credit Strengthened scientific leadership with appointment of Julien Boisdron, MD, Chief Medical Officer of a Swiss Big Pharma, to Scientific Advisory Board Aims to significan
- SECSEC Form 20-F filed by NewcelX Ltd.20-F - NewcelX Ltd. (0001783036) (Filer)
- INSIDERDirector Samuel Olivier bought $225,000 worth of shares (81,818 units at $2.75) (SEC Form 4)4 - NewcelX Ltd. (0001783036) (Issuer)
- INSIDERCSO and Director Revel Michel bought $149,999 worth of shares (54,545 units at $2.75), increasing direct ownership by 6% to 957,530 units (SEC Form 4)4 - NewcelX Ltd. (0001783036) (Issuer)
- SECSEC Form 6-K filed by NewcelX Ltd.6-K - NewcelX Ltd. (0001783036) (Filer)
- PRNewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech ConferenceZURICH, Switzerland, April 20, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL),– NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced the release of an updated corporate presentation that includes the company's strategic collaboration with Eledon Pharmaceuticals (NASDAQ:ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company's development strategy. The updated presentation outlines the integration of NewcelX's scalable stem-cell-derived islet replacement platform with Eledon's investigational anti-CD40L monoclonal antibody tegoprubart, a targ
- SECSEC Form 6-K filed by NewcelX Ltd.6-K - NewcelX Ltd. (0001783036) (Filer)
- PRNewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium PricingFinancing reflects strong investor confidence and supports advancement of lead Type 1 Diabetes program ZURICH, Switzerland, April 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. (NASDAQ:NCEL), a clinical-stage biopharmaceutical company developing stem cell-based therapies for Type 1 Diabetes, today announced that it has entered into securities purchase agreements for a private placement at a purchase price of $2.75 per share, representing a 30% premium to the last closing price of the Company's common shares on March 31, 2026. Pursuant to the terms of the securities purchase agreements, the Company is selling an aggregate of 490,907 common shares (and common share equivalents) and one series o
- INSIDERSEC Form 3 filed by NewcelX Ltd.3 - NewcelX Ltd. (0001783036) (Issuer)
- INSIDERSEC Form 3 filed by NewcelX Ltd.3 - NewcelX Ltd. (0001783036) (Issuer)
- INSIDERSEC Form 3 filed by NewcelX Ltd.3 - NewcelX Ltd. (0001783036) (Issuer)
- INSIDERSEC Form 3 filed by new insider Revel Michel3 - NewcelX Ltd. (0001783036) (Issuer)
NCEL FAQ
5 questionsWhere does NCEL stock trade?
NewcelX Ltd. (NCEL) is listed on NASDAQ.What sector and industry is NCEL in?
NewcelX Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NewcelX Ltd. go public?
NewcelX Ltd. (NCEL) completed its IPO in 2021.What companies are similar to NCEL?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NCEL side-by-side with any of them on Quantisnow.How can I track NCEL on Quantisnow?
Quantisnow aggregates NewcelX Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NCEL to receive live email and push alerts on every new disclosure.